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Human Infections with Novel Influenza A (H7N9) Viruses
Summary and Background
As of April 4, 2013, Chinese public health officials have reported 14 cases of human infection 
with a novel avian influenza A (H7N9) virus from four different provinces in China. All patients 
were hospitalized with severe respiratory illness, and six persons have died. These are the first 
human infections identified with an avian influenza A (H7N9) virus infection. Six cases are from 
Shanghai, one is from Anhui Province, four are from Jiangsu Province, and three are from 
Zhejiang Province. Thirteen cases are in adults aged 27 through 87 years, and one case is in a 
child aged 4 years; all cases had illness onset from February 19 through March 31, 2013. No 
person-to-person transmission or epidemiologic link between any of the cases has been 
identified. We are aware of reports of possible sources of infection but these have not been 
confirmed. We are investigating and will provide that information when it is available.
Preliminary functional data of the isolated viruses from the first 3 cases suggest that they are 
likely susceptible to neuraminidase inhibitors. Investigations by Chinese public health officials 
are ongoing.
These cases are a reminder that novel A influenza viruses can infect and cause severe respiratory 
illness in humans. Novel influenza A viruses are influenza viruses that are different from 
currently circulating human influenza A virus subtypes and include influenza viruses from 
predominantly avian and swine origin. In recent years, human infections with highly pathogenic 
avian influenza A (H5N1) virus in several Asian countries and Egypt, highly pathogenic avian 
influenza A (H7N3) virus in Mexico, and variant influenza A (H3N2)v viruses in the United 
States have been reported
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6136a4.htm
http://www.who.int/influenza/human animal interface/EN GIP 20130312CumulativeNumberH 
5N1cases.pdf
http://emergency.cdc. gov/HAN/han00325.asp.
The clinical presentation of human infection with avian influenza A viruses varies considerably-- 
from mild illness, including conjunctivitis, fever, and cough, to severe illness, including 
fulminant pneumonia leading to death in cases of H5N1 and in these recent cases of H7N9 virus 
infections. To date there has been no evidence of person-to-person transmission of influenza A 
(H7N9) viruses.
At this time, no cases of human infection with avian influenza A (H7N9) viruses have been 
detected in the United States. Rapid detection and characterization of novel influenza viruses 
remain a critical component of national efforts to prevent further cases, evaluate clinical illness
associated with them, and assess any ability for these viruses to spread among humans. As a 
result, clinicians are reminded to consider influenza as a possible diagnosis when evaluating 
patients with acute respiratory illnesses, including pneumonia, even outside of the typical 
influenza season.
Clinicians should consider the possibility of novel influenza A (H7N9) virus infection in persons 
with respiratory illness and an appropriate travel or exposure history. Although the majority of 
novel influenza A (H7N9) cases have resulted in severe respiratory illness in adults, infection 
with this virus may cause mild illness in some and may cause illness in children as well. When 
performing influenza diagnostic testing in patients with respiratory illness for whom an etiology 
has not been confirmed, clinicians may identify human cases of avian influenza A virus infection 
or new cases of variant influenza in the United States. Patients with novel influenza A (H7N9) 
virus infections should have a positive test result for influenza A virus via reverse-transcription 
polymerase chain reaction (RT-PCR) testing but be unsubtypeable.
Suspected infections with novel influenza A (H7N9) viruses in the United States should be 
reported to CDC within 24 hours of initial detection, and state health departments should notify 
CDC promptly of all patients under investigation for possible novel influenza A virus infection.
Interim Recommendations for Clinicians and State and Local Health 
Departments
Case Investigation and Testing
• Patients with illness compatible with influenza who also meet either of the exposure criteria 
below should be candidates for RT-PCR testing for influenza. Decisions about diagnostic 
testing for influenza using RT-PCR should be made using available clinical and 
epidemiologic information, and additional persons in whom clinicians suspect influenza A 
(H7N9) virus infection may also be tested.
1. Patients with recent travel to countries where human cases of novel influenza A (H7N9) 
virus infection have recently been detected, especially if there was recent direct or close 
contact with animals (such as wild birds, poultry, or pigs) or where influenza A (H7N9) 
viruses are known to be circulating in animals. Currently, China is the only country that has 
recently reported novel influenza A (H7N9) human cases.
2. Patients who have had recent contact with confirmed human cases of infection with novel 
influenza A (H7N9) virus.
• Clinicians should obtain a nasopharyngeal swab or aspirate from these patients, place the 
swab or aspirate in viral transport medium, and contact their state or local health department 
to arrange transport and request a timely diagnosis at a state public health laboratory or CDC. 
For additional guidance on diagnostic testing of patients under investigation for novel 
influenza A (H7N9) virus infection, please see Interim Guidance for Laboratory Testing o f
Persons with Suspected Infection with Highly Pathogenic Avian Influenza A (H5N1) Virus in 
the United States at http://www.cdc.gov/flu/avianflu/guidance-labtesting.htm.
• If infection with influenza A (H7N9) virus is suspected based on current clinical and 
epidemiological screening criteria recommended by public health authorities, specimens 
should be collected with appropriate infection control precautions for novel virulent 
influenza viruses and sent to the state or local health department for testing. Viral culture 
should not be attempted in these cases.
• All unsubtypeable influenza A virus specimens should be submitted to CDC immediately for 
additional diagnostic testing. At this time, confirmatory testing for avian influenza A (H7N9) 
will be conducted at CDC.
• Commercially available rapid influenza diagnostic tests (RIDTs) may not detect avian or 
variant influenza A viruses in respiratory specimens. Therefore, a negative rapid influenza 
diagnostic test result does not exclude infection with influenza viruses. In addition, a positive 
test result for influenza A cannot confirm variant or avian influenza virus infection because 
these tests cannot distinguish between influenza A virus subtypes (they do not differentiate 
between human influenza A viruses and avian or variant viruses). Therefore, when RIDTs 
are positive for influenza A and there is concern for novel influenza A virus infection, 
respiratory specimens should be collected and sent for RT-PCR testing at a state public 
health laboratory. Clinical treatment decisions should not be made on the basis of a negative 
rapid influenza diagnostic test result since the test has only moderate sensitivity.
Infection Control
• Clinicians should be aware of appropriate infection control guidelines for patients under 
investigation for infection with novel influenza A viruses. Because it has been shown to 
cause severe respiratory illness in cases identified so far, healthcare personnel (HCP) caring 
for patients under investigation for novel influenza A (H7N9) virus infection should adhere 
to Standard Precautions plus Droplet, Contact, and Airborne Precautions, including eye 
protection, until more is known about the transmission characteristics of the A (H7N9) virus.
• All clusters of respiratory illness in HCP caring for patients with severe acute respiratory 
illness should be investigated.
Treatment
• For persons hospitalized with suspected influenza, including suspected novel H7N9 virus 
infection, clinicians should start empiric treatment with influenza antiviral medications (oral 
oseltamivir or inhaled zanamivir) as soon as possible, without waiting for laboratory 
confirmation.
• For high-risk persons (persons <5 years of age, >65 years of age, and those with certain 
underlying medical conditions) with suspected influenza of any severity , including 
suspected novel H7N9 virus infection, clinicians should start empiric treatment with 
influenza antiviral medications (oral oseltamivir or inhaled zanamivir) as soon as possible, 
without waiting for laboratory confirmation.
• Antiviral treatment is most effective when started as soon as possible after influenza illness 
onset. Early initiation of treatment provides a more optimal clinical response, although 
treatment of moderate, severe, or progressive disease begun after 48 hours of symptoms may 
still provide benefit.
For More Information
• World Health Organization (WHO) “H7N9 avian influenza human infections in China” is 
available at http://www.who.int/csr/don/2013 04 01/en/index.html.
• CDC avian influenza A (H7N9) information page is available at 
http://www.cdc.gov/flu/avianflu/h7n9-virus.htm.
• WHO “Frequently Asked Questions on human infection with A (H7N9) virus, China” is 
available at http://www.who.int/influenza/human animal interface/faq H7N9/en/index.html.
• The Chinese Center for Disease Control and Prevention “Questions and Answers about 
human infection with A(H7N9) avian influenza virus" is available at 
http://www.chinacdc.cn/en/ne/201303/t20130331 79282.html.
• CDC general information about avian influenza viruses and how they spread is available at 
http://www.cdc.gov/flu/avianflu/avian-in-humans.htm.
• CDC “Interim Guidance on Case Definitions to be Used for Investigations of Influenza A 
(H3N2) Variant Virus Cases” for state and local health departments is available at 
http://www.cdc.gov/flu/swineflu/case-definitions.htm.
• CDC “Prevention Strategies for Seasonal and Influenza A (H3N2)v in Health Care Settings” 
is available at http://www.cdc.gov/flu/swineflu/prevention-strategies.htm.
• CDC “Interim Guidance on Specimen Collection, Processing, and Testing for Patients with 
Suspected Influenza A (H3N2)v Virus Infection” for public health professionals is available 
at http://www.cdc.gov/flu/swineflu/h3n2v-testing.htm.
• CDC “Interim Guidance for Enhanced Influenza Surveillance: Additional Specimen 
Collection for Detection of Influenza A (H3N2) Variant Virus Infections” for state and local 
health departments is available at http://www.cdc.gov/flu/swineflu/h3n2v-surveillance.htm.
• National Association of State Public Health Veterinarians “Compendium of Measures to 
Prevent Disease Associated with Animals in Public Settings, 2011” is available as the first 
bulleted item at http://nasphv.org/documentsCompendiumAnimals.html.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
partnerships with local, national and international organizations.
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